Premalignant and malignant disease of the breast: The roles of the pathologist

Modern Pathology

Volumn 11, Issue 2, 1998, Pages 120-128

  Page, David L ^a   Jensen, Roy A ^a,b   Simpson, Jean F ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast; Breast cancer; Premalignant; Prognosis; Surgical pathology

Indexed keywords

ESTROGEN RECEPTOR;

BREAST DISEASE; CANCER RISK; FEMALE; GENETIC MARKER; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MALIGNANT TRANSFORMATION; PATHOLOGIST; PRECANCER; PRIORITY JOURNAL; REVIEW;

BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERPLASIA; LYMPHATIC METASTASIS; PATHOLOGY, SURGICAL; PRECANCEROUS CONDITIONS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0031915186     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Dupont WD, Plummer WD. Understanding the relationship between relative and absolute risk. Cancer 1996;77:2193-9.
2. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
3. Morrow M. Precancerous breast lesions: implications for breast cancer prevention trials. Int J Radiat Oncol Biol Phys 1991;23:1071-8.
4. Page DL, Jensen RA. Ductal carcinoma in situ of the breast: understanding the misunderstood stepchild. JAMA 1996;275: 948-9.
5. Page DL, Steel CM, Dixon JM. ABC of breast diseases: carcinoma in situ and patients at high risk of breast cancer. BMJ 1995;310:39-42.
6. Tavassoli FA. Atypical hyperplasia: a morphologic risk factor for subsequent development of invasive breast carcinoma. Cancer Invest 1992;10:433-41.
7. Kelsey JL, Gammon MD. Epidemiology of breast cancer. Epidemiol Rev 1990;12:228-40.
8. London SJ, Connolly JL, Schnitt SL, Colditz GA. A prospective study of benign breast disease and risk of breast cancer. JAMA 1992;267:941-4.
9. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast: a long- follow-up study. Cancer 1985;55:2698-708.
10. McDivitt RW, Stevens JA, Lee PC, Wing PA, Rubin GL, Gersell D. Cancer and steroid hormone study group: histologic types of benign breast disease and the risk for breast cancer. Cancer 1992;69:1408-14.
11. Page DL, Dupont WD. Anatomic markers of human premalignancy and risk of breast cancer. Cancer 1990;66:1326-35.
12. Dupont WD, Page DL, Parl FF, Vnencak JC, Plummer WJ, Rados MS, et al. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 1994;331:10-5.
13. Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol 1992;23:1095-7.
14. Marshall LM, Hunter DJ, Connolly JL, Schnitt SJ, Byrne C, London SJ, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 1997;6:297-301.
15. Palli D, Rosselli del Turco M, Simoncini R, Bianchi S. Benign breast disease and breast cancer: a case-control study in a cohort in Italy. Int J Cancer 1991;47:703-6.
16. Hutter R. Consensus meeting: is "fibrocystic disease" of the breast precancerous? Arch Path Lab Med 1986;110:171-3.
17. Poller DN, Ellis IO. Ductal carcinoma in situ (DCIS) of the breast. In: Kirkham N, Lemoine NR, editors. Progress in pathology, vol 2. Edinburgh: Churchill Livingstone: 1995. p. 47-87.
18. Anderson TJ, Page DL. Risk assessment in breast cancer. In: Anthony PP, MacSween RNM, Lowe DG, editors. Recent advances in histopathology, vol 17. Edinburgh: Churchill Livingstone; 1997. p. 69-91.
19. Sneige N, Staerkel GA. Fine-needle aspiration cytology of ductal hyperplasia with and without atypia and ductal carcinoma in situ. Hum Pathol 1994;25:485-92.
20. Stanley MW, Henry SM, Zera R. Atypia in breast fine-needle aspiration smears correlates poorly with the presence of a prognostically significant proliferative lesion of ductal epithelium. Hum Pathol 1993;24:630-5.
21. Salhany KE, Page DL. Fine-needle aspiration of mammary lobular carcinoma in situ and atypical lobular hyperplasia. Am J Clin Path 1989;92:22-6.
22. Schnitt SJ, Connolly JL, Tavassoli FA, Fechner RE, Kempson RL, Gelman R, et al. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol 1992;16:1133-43.
23. Page DL, Kidd TE, Dupont WD, Simpson JF, Rogers LW. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 1991;22:1232-9.
24. Foote FW, Stewart FW. Lobular carcinoma in situ. Am J Pathol 1941;17:491-5.
25. Bodian CA, Perzin KH, Lattes R. Lobular neoplasia: long-term risk of breast cancer in relation to other factors. Cancer 1996;78:1024-34.
26. Rosen PP, Braun DWJ, Lyngholm B, Urban JA, Kinne DW. Lobular carcinoma in situ of the breast: preliminary results of treatment by ipsilateral mastectomy and contralateral breast biopsy. Cancer 1981;47:813-9.
27. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312:146-51.
28. Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfleld AC, Worrell JA. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993;71: 1258-65.
29. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15 to 25 years after a diagnosis of low-grade ductal carcinoma in situ of the breast treated by biopsy only. Cancer 1995;76:1197-200.
30. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, et al. Prognostic classification of breast ductal carcinoma in situ. Lancet 1995;345:1154-7.
31. Lagios MD. Heterogeneity of duct carcinoma in situ (DCIS): relationship of grade and subtype analysis to local recurrence and risk of invasive transformation. Cancer Lett 1995; 90:97-102.
32. Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Cancer 1989;63: 618-24.
33. Scott MA, Lagios MD, Axelsson K, Rogers LW, Anderson TJ, Page DL. Ductal carcinoma of the breast: reproducibility of histologic subtype analysis [abstract]. Mod Pathol 1995;8: 25A.
34. Connolly JL, Fechner RE, Kempson RL, LiVolsi VA, Page DL, Patchefsky AA, et al. Recommendations for the reporting of breast carcinoma. Am J Clin Pathol 1995;104:614-9.
35. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver M, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994;11:167-80.
36. Fechner RE. One century of mammary carcinoma in situ: what have we learned? Am J Clin Pathol 1993;100:654-61.
37. Douglas-Jones AG, Gupta SK, Attanoos RL, Morgan JM, Mansel RE. A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS): correlation with grade of associated invasive carcinoma. Histopathology 1996;29:397-409.
38. Patchefsky AS, Schwartz GF, Finkelstein SD, Prestipino A, Sohn SE, Singer JS, et al. Heterogeneity of intraductal carcinoma of the breast. Cancer 1989;63:731-41.
39. Bellamy C, McDonald C, Salter DM, Chetty U, Anderson TJ. Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization. Hum Pathol 1993;24:16-23.
40. Souvinos G, Kiaris H, Tsikkinis A, Vassilaros S, Spandidos DA. Microsatellite instability and loss of heterozygosity in primary breast tumours. Tum Biol 1997;18:157-66.
41. Rosenberg CL, Larson PS, Romo JD, de las Morenas A, Faller DV. Microsatellite alterations indicating monoclonality in atypical hyperplasias associated with breast cancer. Hum Pathol 1997;28:214-9.
42. Lakhani SR, Slack DN, Hamoudi RA, Collins MR, Sloane JP. Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal neoplastic proliferations. Lab Invest 1997;74:129-35.
43. Kasami M, Vnencak-Jones CL, Manning S, Dupont WD, Page DL. Loss of heterozygosity and microsatellite instability in breast hyperplasia: no obligate correlation of these genetic alterations with subsequent malignancy. Am J Pathol 1997; 150:1925-32.
44. Henson DE, Fielding P, Grignon DJ, Page DL, Hammond ME, Nash G, et al. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Arch Pathol Lab Med 1995;119:1109-12.
45. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66.
46. 0) breast carcinoma. J Clin Oncol 1989;7:355-66.
47. Arnesson L-G, Hatschek T, Smeds S, Grontoft O. Histopathology grading in small breast cancers less than 10 mm: results from an area with mammography screening. Breast Cancer Res Treat 1997;44:39-46.
48. 0): clinicopathologic features and outcome. Cancer 1996;76:761-71.
49. Cady B. Use of primary breast carcinoma characteristics to predict lymph node metastases. Cancer 1997;79:1856-61.
50. Seidman JD, Schnaper LA, Aisner SC. Relationship of the size of the invasive component of the primary breast carcinoma to axillary lymph node metastasis. Cancer 1995;75:65-71.
51. Fisher B, Bauer M, Wickerham L, Redmond CK, Fisher ER, Cruz AB. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: an NSABP Update. Cancer 1983;52:1551-7.
52. van Bogaert L-J. Immunohistochemical detection and significance of axillary lymph node micrometastases in breast carcinoma. Anal Quant Cytol Histol 1995;17:75-6.
53. de Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: re-evaluation with longer follow-up. Br J Cancer 1992;66:523-7.
54. Donegan WL, Stine SB, Samter TG. Implications of extracapsular nodal metastases for treatment and prognosis of breast cancer. Cancer 1993;72:778-82.
55. Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT. The Nottingham Prognostic Index applied to 9149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat 1994;32:281-90.
56. Dixon JM, Page DL, Anderson TJ, Lee D, Elton RA, Stewart HJ, et al. Long-term survivors after breast cancer. Br J Surg 1985;72:445-8.
57. Pereira H, Pinder SE, Sibbering DM, Galea MH, Elston CW, Blamey RW, et al. Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995;27:219-26.
58. Pedersen L, Holck S, Schiodt T, Zedeler K, Mouridsen HT. Medullary carcinoma of the breast: prognostic importance of characteristic histopathological features evaluated in a multivariate Cox analysis. Eur J Cancer 1994;30A:1792-7.
59. Page DL. Prognosis and breast cancer: recognition of lethal and favorable prognostic types. Am J Surg Pathol 1991;15: 334-49.
60. Mansour EG, Ravdin PM, Dressler L. Prognostic factors in early breast carcinoma. Cancer 1994;74:381-400.
61. Pinder SE, Ellis IO, Elston CW. Prognostic factors in primary breast carcinoma. J Clin Pathol 1995;48:981-3.
62. Simpson JF, Page DL. Status of breast cancer prognostication based on histopathologic data. Am J Clin Pathol 1994; 102 (4 Suppl 1):S3-S8.
63. Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, et al. Assessment of the new proliferation marker MIB-1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 1995;71:146-9.
64. Wold LE, Ingle IN, Pisansky TM, Johnson RE, Donohue JH. Prognostic factors for patients with carcinoma of the breast. Mayo Clin Proc 1995;70:678-9.
65. Dalton LW, Page DL, Dupont WD. Histologic grading of breast carcinoma: a reproducibility study. Cancer 1994;73: 2765-70.
66. Contesso G, Mouriesse H, Friedman S, Genin I, Sarrazin D, Rouesse J. The importance of histologic grade in long-term prognosis of breast cancer: a study of 1010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 1987;5:1378-86.
67. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
68. Elston CW, Ellis IO. Method for grading breast cancer. J Clin Pathol 1993;46:189-90.
69. Barbareschi M, Caffo O, Veronese S, Leek RD, Fina P, Fox S, et al. bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol 1996; 27:1149-55.
70. Kollias J, Elston CW, Ellis IO, Robertson JFR, Blamey RW. Early-onset breast cancer: histopathological and prognostic considerations. Br J Cancer 1997;75:1318-23.
71. Wolberg WH, Street WN, Heisey DM, Mangasarian OL. Computerized breast cancer diagnosis and prognosis from fine-needle aspirates. Arch Surg 1995;130:511-6.
72. Esteban JM, Ahn C, Battifora H, Felder B. Predictive value of estrogen receptors evaluated by quantitative immunohistochemical analysis in breast cancer. Am J Clin Pathol 1994;102 (4 Suppl 1):S9-S12.
73. Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoma: mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67, and MIB-1. Am J Clin Pathol 1995;104:42-9.
74. Page DL, Simpson JF. Measure of proliferation in breast cancer: practicality and utility. Breast 1997;6:169-70.
75. Conner AJM, Pinder SE, Elston CW, Bell JA, Wencyk P, Robertson JFR, et al. Intratumoral heterogeneity of proliferation in invasive breast carcinoma evaluated with MIB-1 antibody. Breast 1997;6:171-6.
76. Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, et al. Assessment of the new proliferation marker, MIB-1, in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 1995;71:146-9.
77. Axelsson K, Ljung BM, Moore DH II, Thor AD, Chew KL, Edgerton SM, et al. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 1995;87:997-1008.
78. Costello P, McCann A, Carney DN, Dervan PA. Prognostic significance of microvessel density in lymph node-negative breast carcinoma. Hum Pathol 1995;26:1181-4.
79. Simpson JF, Ahn C, Battifora H, Esteban JM. Endothelial area as a prognostic indicator for invasive breast carcinoma. Cancer 1996;77:2077-85.
80. Clemente CG, Boracchi P, Andreola S, del Vecchio M, Veronesi P, Rilke FO. Peritumoral lymphatic invasion in patients with node-negative mammary duct carcinoma. Cancer 1992; 69:1396-403.
81. Miller WR, Ellis IO, Sainsbury J, Dixon JM. ABC of breast diseases: prognostic factors. BMJ 1994;309:1573-6.